anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive ruxolitinib PO BID and enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT and bone scan throughout the study. Patients may also undergo a tissue biopsy on study.
We conducted a pilot randomized, double-blind, placebo-controlled trial with crossover in survivors of pediatric brain tumors with primary endpoints of safety and feasibility and secondary endpoints of cognitive and magnetic resonance imaging (MRI) measures. Twenty-four participants were enrolled and randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either a group AB (AB) or group BA (BA) sequence. At the point of crossover, there was a 10-week washout period in which neither group received any treatment. During the first week of each treatment cycle, a daily dose of 500 mg/m2 of metformin or placebo was administered orally. The dose was increased to 1000mg/m2 daily beginning in the second week and continuing for the remainder of the 12-week cycle.

Test procedures (Clinical \& current medications reviews, Blood draws, and MRI and Cognitive testing) were performed at 4 times points during the study: 1. at study entry (Baseline 1), 2. after 12 weeks of treatment (Outcome 1), 3. after a 10-week washout period at 22 weeks (Baseline 2), and 4. At the end of the trial at 34 weeks (Outcome 2).
In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
* Reduce moderate to severe hot flashes.  Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the “change of life” or menopause (the end of monthly menstrual periods). Sometimes both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes “surgical menopause.”

When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and sweating (“hot flashes” or “hot flushes”). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether you still need treatment with PREMARIN.

  * Treat moderate to severe dryness, itching, and burning, in and around the vagina. You and your healthcare provider should talk regularly about whether you still need treatment with PREMARIN to control these problems. If you use PREMARIN only to treat your dryness, itching, and burning in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.
  * Help reduce your chances of getting osteoporosis (thin weak bones). Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use PREMARIN only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you should continue with PREMARIN.

Weight-bearing exercise, like walking or running, and taking calcium and vitamin D supplements may also lower your chances for getting postmenopausal osteoporosis. It is important to talk about exercise and supplements with your healthcare provider before starting them.
Because of the risks of hepatotoxicity and birth defects, TRACLEER is available only through a restricted program called the Bosentan REMS Program. Under the Bosentan REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions (5.3)] . 

Hepatotoxicity

In clinical studies, TRACLEER caused at least 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly [see Dosage and Administration (2.4), Warnings and Precautions (5.1)] . In the postmarketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (>12 months) therapy with TRACLEER in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of TRACLEER in these cases could not be excluded. 

In at least one case, the initial presentation (after >20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of TRACLEER. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping TRACLEER with a rise of aminotransferases accompanied by signs or symptoms of liver dysfunction [see Dosage and Administration (2.4)] . 

Elevations in aminotransferases require close attention [see Dosage and Administration (2.4)] . TRACLEER should generally be avoided in patients with elevated aminotransferases (>3×ULN) at baseline because monitoring for hepatotoxicity may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥2×ULN, treatment with TRACLEER should be stopped. There is no experience with the reintroduction of TRACLEER in these circumstances. 

Embryo-Fetal Toxicity

TRACLEER is likely to cause major birth defects if used by pregnant females based on animal data [see Warnings and Precautions (5.2), Use in Specific Populations (8.1)] . Therefore, pregnancy must be excluded before the start of treatment with TRACLEER. Throughout treatment and for one month after stopping TRACLEER, females of reproductive potential must use two reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization, in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving TRACLEER [see Drug Interactions (7.2)] . Obtain monthly pregnancy tests.
A non-rinse hair care formulation comprising an oil adsorber and water, wherein the propellant comprises compressed gas is provided. The compressed gas may be compressed air. The adsorber may be a starch selected from one or more of corn starch, modified corn starch, tapioca starch, rice starch or modified rice starch. The oil adsorber may be zeolite or insoluble polyvinylpolypyrrolidone. The preferred oil adsorber is distarch phosphate. The formulation may comprise ethanol. The formulation may comprise betaine. A dry shampoo comprising the formulation is provided. A hair care pack comprising the formulation is provided. A dry shampoo formulation for use with compressed gas propellant, comprising distarch phosphate as an oil adsorber present in an amount in the range 10% to 25%, and water to 100% is provided. A preferred compressed gas formula comprises distarch phosphate, betaine, ethanol, and water. The composition may further comprise hair conditioner ingredients. Formulations comprising dimethyl ether as an alternative propellant are disclosed.
The invention discloses an ointment for treatment of erythrodermic psoriasis and a preparation method thereof. The ointment comprises, by weight, 100-10 parts of radix cynanchi atrati, 100-10 parts of dendrobe, 100-10 parts of bistort rhizome, 100-10 parts of folium mori and 3000-150 parts of petrolatum jelly. The preparation method includes the following steps: firstly heating the petrolatum jelly until melting down, mixing the radix cynanchi atrati, dendrobe, bistort rhizome, and folium mori into the petrolatum jelly and soaking for 6 days, then heating the mixture until the mixture turns into brown, taking out the mixture residue when the temperature is 150-100 DEG C, waiting the medicinal oil cooling and drying to condensate into ointment, packing with plastic case for readily use. The ointment has the advantages of the direct smearing of the ointment on the lesions and has the advantageous effects of removing pathogenic heat from blood, nourishing yin and moisturizing skin and expelling wind and relieving convulsion. Based on the patient's responses after taking the ointment the skin feels comfortable and well nourished. The ointment can soften the scale, make the skin desquamation subside gradually. The ointment has no stimulating effects to the skin and has the function of skin protection.
Clinical monitoring will be conducted by telephone and include a 15-20 minutes discussions of how the participant has been feeling over the past two weeks. A standard format will be used for conducting the clinical monitoring telephone calls. TAU will include treatment based on the recommendation of participants' healthcare provider/team.
Intrauterine insemination is a procedure that is performed in the physician's office. During the procedure the sperm from the male partner are placed directly into the female partner's uterus around the time of ovulation (release of oocyte or egg). Ovulation predictor kits, available over the counter at pharmacies, test for the presence of luteinizing hormone in the urine. When the test result is a positive, it means the hormone is present in the urine. This is a sign of ovulation. Physicians typically choose to perform intrauterine insemination either the day of a positive ovulation test or the day after a positive ovulation test. The purpose of this study is to determine if the day when intrauterine insemination is performed influences the chance of becoming pregnant.
Medical product (A) comprises a dose of tiotropium (I), as dry powder, filled directly into a container, formed from a high-security seal that prevents entry of moisture so that the original proportion of fine particles in the powder is retained. The dose of (I) is suitable for administration using a dry powder inhaler. Independent claims are also included for: (1) Pharmaceutical composition (A1) comprising (I), or its salt, and a pharmaceutical carrier (II) that is filled directly into a dry, moisture-proof package or dry, sealed container so that the original proportion of fine particles in the powder is retained; and (2) Medical product, similar to (A), or composition similar to (A1), that includes another pharmaceutical (III), separately or together with (I), and optionally (II). ACTIVITY : Antiinflammatory; Antiasthmatic. No details of tests for these activities are given. MECHANISM OF ACTION : None given.
Neutrophils are emerging as an important player in skeletal muscle injury and repair. Neutrophils accumulate in injured tissue, thus releasing inflammatory factors, proteases and neutrophil extracellular traps (NETs) to clear muscle debris and pathogens when skeletal muscle is damaged. During the process of muscle repair, neutrophils can promote self-renewal and angiogenesis in satellite cells. When neutrophils are abnormally overactivated, neutrophils cause collagen deposition, functional impairment of satellite cells, and damage to the skeletal muscle vascular endothelium. Heterotopic ossification (HO) refers to abnormal bone formation in soft tissue. Skeletal muscle injury is one of the main causes of traumatic HO (tHO). Neutrophils play a pivotal role in activating BMPs and TGF-β signals, thus promoting the differentiation of mesenchymal stem cells and progenitor cells into osteoblasts or osteoclasts to facilitate HO. Furthermore, NETs are specifically localized at the site of HO, thereby accelerating the formation of HO. Additionally, the overactivation of neutrophils contributes to the disruption of immune homeostasis to trigger HO. An understanding of the diverse roles of neutrophils will not only provide more information on the pathogenesis of skeletal muscle injury for repair and HO but also provides a foundation for the development of more efficacious treatment modalities for HO.
FIELD: medicine, pharmaceutical technology, pharmacy. SUBSTANCE: invention relates to the improved method for purification of highly effective antituberculosis preparation ethambutol. Method involves crystallization of ethambutol from lower aliphatic alcohol acidified preliminary with hydrogen chloride to the concentration 1.0-1.5 wt.-%. Method provides the enhanced yield of the end product as compared with early known methods and to retain high quality of preparation. EFFECT: improved purification method. 5 ex
The invention relates to the field of traditional Chinese medicine extraction and separation, in particular to two novel alkaloid compounds extracted, separated and identified from purslane and an extraction and separation method thereof. The molecular formula of the alkaloid compound is C respectively  15  H  25  NO  6  And C  9  H  15  NO, designated as (Z) -2- ((1- (1H-azirin-1-yl) -5-methylhex-1-en-3-yl) oxy) -6- (hydroxyymethyl) tetrahydro-2H-pyran-3,4,5-triol and (Z) -1- (1H-azirin-1-yl) -5-methylhex-1-en-3-ol, respectively. Also provides an extraction and separation method of the two new alkaline compounds, which sequentially adopts water decoction and extraction, macroporous resin column chromatography, ODS medium-pressure column, sephadex LH-20 and HPLC for separation, purification and preparation. Two new alkaloid compounds are successfully extracted and separated. The structure is determined by a carbon spectrum, a hydrogen spectrum and a two-dimensional nuclear magnetic wave spectrum analysis method. The two compounds have potential anti-inflammatory activity and anticholinesterase activity, provide preparation methods, and provide a lead and theoretical basis for developing new drugs and developing new components.
Post-operative analgesia after anorectal surgery still poses a significant problem. Technical or operator dependent factors have been proposed for causing severe pain post operatively. Many factors such as height of anastomosis, incorporation of smooth muscle, size of doughnut, and inclusion of squamous epithelium were considered to cause pain specially after hemorrhoidectomy. However, in spite of standardizing the techniques, patients still experience moderate to severe pain after anorectal surgery. Effective post-surgical pain control is critical to patient recovery, and can contribute to improved healing, faster patient mobilization, reduced hospital stays and health care costs. Effective multimodal techniques have been devised to maximize pain relief, lower the risk of adverse events, and improve patient outcomes. These techniques (wound infiltration with local anesthetic being most common) is short lived, maximum up to 12 hours. Post-operative pain usually lasts for 72 hours and thus the systemic opioids remain the mainstay pain control post-operatively. Although effective analgesics, they are associated with unwanted and potentially adverse events, such as nausea, vomiting, pruritus, sedation, cognitive impairment, urinary retention, sleep disturbances, and respiratory depression. Also, narcotic addiction remains a concern for surgical patients. Some patients would like to have effective analgesia and thus also avoid narcotics.Multi-drug analgesic combinations are used in orthopedic surgery (Ropivacaine, Ketorolac, and Morphine, with adrenaline) and during hemorrhoidectomy (extended-release liposome Bupivacaine) which showed decrease in post-operative analgesia requirement. However, no studies that used multi-drug analgesia show any effect on the pain medication consumption after discharge for ambulatory surgery. The investigators have designed a novel multi-drug anesthetic formulation to achieve long-acting postoperative analgesia with single-dose administration intra-operative via perianal block and wound infiltration.
For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day \~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
BACKGROUND: Peritoneal fluid lactate concentration is an important diagnostic tool in horses with abdominal pain. Information on peritoneal lactate concentrations is lacking following parturition in the mare.
OBJECTIVES: To compare blood and peritoneal lactate concentrations in a population of mares within 36 h post-partum, report a normal reference range and identify any impact of retained foetal membranes (RFMs).
METHODS: This is a retrospective study evaluating healthy mares from which blood and peritoneal samples had been obtained within 36 h of parturition. Exclusion criteria included signs of abdominal pain within this period. Data was interrogated for normality using a Shapiro-Wilk test. Wilcoxon signed-rank test and Bland-Altman analysis were used to compare blood and peritoneal lactate concentrations. Linear regression was used to compare age and breed data with peritoneal lactate concentrations. Significance was defined as p < 0.05.
RESULTS: Forty mares met the inclusion criteria. Mean age was 12.6 ± 4.1 years, and most mares were multiparous (65%). Peritoneal lactate ((1.2 (IQR = 0.9-1.6) mmol/L) was increased compared to blood lactate concentration (0.7 (IQR = 0-1.1)mmol/L; p < 0.001). Plasma total protein (TP) concentrations were 68 (IQR = 64-74) g/L and peritoneal protein concentrations 8 (IQR = 4-9.7) g/L. Six mares developed RFM. The median fold-increase in peritoneal lactate concentration compared to blood lactate concentration was 0.9 (IQR: 0.01-1.7; range: 0-2.5). The reference range for peritoneal fluid lactate concentration was 0-2.5 mmol/L.
CONCLUSION: Peritoneal lactate concentrations in healthy post-partum mares remained within the normal reference range and were not influenced by RFM or parturition. Increased peritoneal lactate in this group warrants further investigation.
Myeloid-derived growth factor (MYDGF) is a novel secreted protein with potent antiapoptotic and tissue-repairing properties that is present in nearly 140 human tissues and cell lines, with the highest abundance in the oral epithelium and skin. Initially, MYDGF was found in bone marrow-derived monocytes and macrophages for cardioprotection and repair after myocardial infarction. Subsequent studies have shown that MYDGF plays an important role in other cardiovascular diseases (e.g., atherosclerosis and heart failure), metabolic disorders, renal disease, autoimmune/inflammatory disorders, and cancers. Although the underlying mechanisms have not been fully explored, the role of MYDGF in health and disease may involve cell apoptosis and proliferation, tissue repair and regeneration, anti-inflammation, and glycolipid metabolism regulation. In this review, we summarize the current progress in understanding the role of MYDGF in health and disease, focusing on its structure, function and mechanisms. The graphical abstract shows the current role of MYDGF in different organs and diseases (Fig. 1).
The purpose of this study is to find the highest dose of romidepsin that can safely be given in combination with gemcitabine, dexamethasone, and cisplatin (GDP) without causing very severe side effects that are not tolerable. This is done by starting at a dose lower than the one that does not cause side effects in animals. Patients are given romidepsin and GDP and watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more patients are asked to join the study and are given a higher dose of romidepsin (with GDP). Patients joining the study later on will get higher doses of romidepsin (with GDP) than patients who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.
In embodiments, the disclosure relates to methods of ameliorating or preventing a disease or disease condition. Generally, the methods involve administering a composition having a synthetic lysine analog, derivative, or mimetic. In some embodiments, the synthetic lysine analog, derivative, or mimetic interacts with cells associated with a disease or disease condition to inhibit or prevent replication, survival, or formation of the cells. In another embodiment, the disclosure relates to compositions having synthetic lysine analogs, derivatives, or mimetics for ameliorating or preventing a disease or disease condition. In further embodiments, the disclosure relates to methods and compositions having synthetic lysine analogs, derivatives, or mimetics for improving aging. In additional embodiments, the disclosure relates to methods and compositions having synthetic lysine analogs, derivatives, or mimetics for the treatment and prevention of cancer.
A method for purifying bone-derived osteoinductive factors including an ultrafiltration process, an anion exchange process, a cation exchange process, and a reverse phase HPLC process. The ultrafiltration process preferably includes a first ultrafiltration step using a membrane having a nominal molecular weight cutoff of approximately 100 kilodaltons (kD) and a second ultrafiltration step employing a membrane having a nominal molecular weight cutoff of approximately 10 kD. For the anion exchange process, a strongly cationic resin is used, preferably having quaternary amine functional groups. Typically, the eluant for the anion exchange process has a conductivity from about 10,260 micromhos ($g(m)mhos) (1.026 x 10?-2 siemens (S)) to about 11,200 $g(m)mhos (1.120 x 10?-2 S). For the cation exchange process, a strongly anionic resin is used, preferably having sulfonic acid functional groups. The eluant for the cation exchange process typically has a conductivity from about 39,100 $g(m)mhos (3.91 x 10?-2 S) to about 82,700 $g(m)mhos (8.27 x 10?-2 S) or more. The HPLC process typically utilizes a column containing hydrocarbon-modified silica packing material. The osteoinductive proteins can be eluted from the HPLC column with an acetonitrile solution in combination with aqueous trifluoracetic acid. The purification processes yield osteoinductively active protein mixtures.
Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
Flavored ketone ester beverage 75 mL. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.